Eli Lilly has made history by becoming the first health-care company in the world to reach a $1 trillion market capitalization, briefly touching the milestone during Friday morning trading. Shares surged past the mark before settling around $1,048, cementing the drugmaker’s position among an elite group of mostly tech-driven giants. It is only the second non-tech firm in the U.S.—after Berkshire Hathaway—to achieve this valuation.
The pharmaceutical company’s meteoric rise has been powered by unprecedented demand for its blockbuster drugs Mounjaro, a diabetes treatment, and Zepbound, a weight-loss injection. These GLP-1 medications have reshaped the global obesity and diabetes market, helping Eli Lilly outpace its closest competitor, Novo Nordisk. Investors have responded enthusiastically, pushing the stock up more than 36% so far this year.
Financial performance has been extraordinary. In the latest quarter, Mounjaro generated $6.52 billion in revenue—up 109% from a year earlier—while Zepbound reported $3.59 billion, a staggering 184% jump. Analysts expect demand to soar further as approvals broaden and insurance coverage expands. Eli Lilly is also preparing to launch an oral version of these treatments next year, promising easier production and more convenience for patients.
These successes position Eli Lilly to dominate a weight-loss drug market projected to exceed $150 billion by the early 2030s. Still, competition remains fierce: Novo Nordisk continues to advance its own GLP-1 drugs, and Pfizer recently intensified its push by acquiring Metsera for $10 billion.
Founded in 1876, Eli Lilly has a long history of medical breakthroughs—from producing the first commercial insulin in 1923 to developing Prozac and early polio vaccines. But the approval of tirzepatide in 2022 marked a turning point. Sold as Mounjaro for diabetes and Zepbound for obesity, the drug mimics two hormones—GLP-1 and GIP—to suppress appetite and improve how the body processes sugar and fat, giving it an edge over rival semaglutide-based treatments.
By 2024, Eli Lilly’s new-generation drugs were generating blockbuster sales: $11.54 billion for Mounjaro and $4.93 billion for Zepbound. With momentum accelerating, the company’s leap into the trillion-dollar club reinforces its status as the most influential force in modern pharmaceuticals.